HypotensionNCT01309724
Hemodynamic Optimization By Non-Invasive Determination Of Cardiac Output In Critically Ill Patients
A study testing USCOM-guided fluid administration in people with Hypotension, run by Washington University School of Medicine at 1 site in United States.
Trial summary
Inadequate identification of and subsequent delayed therapy for patients with hypoperfusion (including hypovolemia, congestive heart failure and sepsis) is a common problem faced by physicians and intensivists caring for critically ill patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hypotension
- What is being tested?
- USCOM-guided fluid administration
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 92 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2010to Dec 2010
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 yrs or greater
- Administration of vasopressors, defined as a continuous infusion of norepinephrine at a dose >5 mcg/min, dopamine ≥5 mcg/kg/min or any dose of another vasopressor
- Passage of <18 hours since initiation of vasopressors at doses specified above
Who cannot join
- Hemorrhagic shock
- Need for immediate surgery
- Imminent risk of death in the next 48 hours (as judged by the attending ICU physician)
- Level of care decision that precluded implementation of the study protocol
- Enrollment in any other clinical study
- Pregnancy
Trial locations and contacts
1 site in 1 country.
About this study
Official title: HEMODYNAMIC OPTIMIZATION BY NON-INVASIVE DETERMINATION OF CARDIAC OUTPUT IN CRITICALLY ILL PATIENTS: A RANDOMIZED, CONTROLLED TRIAL
Inadequate identification of and subsequent delayed therapy for patients with hypoperfusion (including hypovolemia, congestive heart failure and sepsis) is a common problem faced by physicians and intensivists caring for critically ill patients. Bedside clinical assessment is notoriously inaccurate in diagnosing complex etiologies of hemodynamic disturbances and in deciding on the appropriate therapy. Invasive techniques which are often required to guide diagnosis and therapy have significant risks associated with them, are costly, and are time consuming. New technology has been developed that allows for instantaneous, noninvasive monitoring of key hemodynamic parameters, like stroke volume, peak velocity and cardiac output. This new technology has the potential to improve recognition of the etiology of hemodynamic disturbances and assist the clinician in optimizing therapy based on changes in hemodynamic parameters. There is significant potential for this to be translated into improved outcomes in critically ill patients, but this has never been studied.
Read the detailed description
Patients with life-threatening hypotension are commonly cared for in intensive care units (ICUs). Pathophysiologic perturbations due to disease states such as sepsis, hypovolemia, and congestive heart failure may lead to tissue hypoxia, a critical development which precedes multi-organ failure and death. Not only is it difficult to rapidly identify patients heading down this path, but the execution of effective hemodynamic resuscitation to slow or reverse this process is challenging.
A cornerstone of hemodynamic resuscitation is volume administration. The goal of volume administration is to maximize cardiac output, and thereby systemic oxygen delivery, by optimizing cardiac preload. Bedside clinical assessment is inadequate for judging whether or not this goal has been achieved. Invasive techniques, such as central venous pressure (CVP) monitoring and pulmonary artery catheterization, carry risks, are costly and time-consuming, and may yield misleading data. Doppler ultrasound-based technology has been developed that allows for instantaneous, non-invasive monitoring of key hemodynamic parameters, such as cardiac output. This technology may facilitate determining the etiology of hemodynamic disturbances and assist the clinician in optimizing therapy based on changes in hemodynamic parameters. This randomized, controlled trial was designed to determine the impact of a volume resuscitation protocol, guided by non-invasive Doppler ultrasound technology, on outcomes in medical ICU patients with vasopressor-dependent hypotension.
Materials and methods:
Patient Population:
Study participants were recruited between January 19, 2010 and December 26, 2010 from two medical ICUs at Barnes-Jewish Hospital, a 1252-bed urban teaching hospital. The Washington University School of Medicine Human Research Protection Office approved the study, and informed consent was obtained from participants or their authorized representatives. Inclusion criteria were age ≥18 years; administration of vasopressors, defined as a continuous infusion of norepinephrine at a dose >5 mcg/min, dopamine ≥5 mcg/kg/min or any dose of another vasopressor; and passage of <18 hours since initiation of vasopressors at doses specified above. Exclusion criteria were hemorrhagic shock, need for immediate surgery, imminent risk of death in the next 48 hours (as judged by the attending ICU physician), level of care decision that precluded implementation of the study protocol, enrollment in any other clinical study, and pregnancy.
Study Protocol:
Subjects were assigned to treatment groups using blocked randomization to receive either volume resuscitation guided by the ultrasound cardiac output monitor (USCOM; USCOM Ltd., Sydney, Australia) or observation. The USCOM is a non-invasive device that uses continuous-wave Doppler ultrasound measurements of blood flow in the ascending aorta or pulmonary artery to estimate stroke volume (SV). Prior to the beginning of the study, one of the study investigators (LMD) underwent a supervised training period with the USCOM in 50 patients to insure reproducibility of the obtained measurements. Subjects randomized to the intervention group underwent a baseline USCOM measurement of SV by a single operator (LMD), followed by a pressurized infusion of 1 L of normal saline (NS) over approximately 15 minutes, after which the SV measurement was repeated. If the SV increased by ≥15%, the patient was deemed volume-responsive, and another 1 L NS bolus was administered. This process was repeated until the SV did not increase by ≥15%, two hours had elapsed since study enrollment, or 4 L of NS had been infused, whichever occurred first. With the exception of initial fluid management in the intervention group, as described above, use of all diagnostic and treatment modalities were at the discretion of the ICU physicians. Subjects in the control group underwent no intervention; ongoing care was carried out at the discretion of the ICU physicians. ICU physicians were unaware of subjects' group assignments and the USCOM data acquired in the intervention group.
- Conditions
- Hypotension
- Being tested
- USCOM-guided fluid administration
- Keywords
- Hypotension, Fluid
- Medical subject headings
- Hypotension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
USCOM-guided fluid administrationOther
Also called Ultrasound cardiac output monitor
Patients in the intervention group underwent hemodynamic measurements with the ultrasound cardiac output monitor. Based on these measurements, patients were guided through a fluid resuscitation protocol.
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | No measurements are made on the control group. |
| USCOM | Experimental | Patients undergo hemodynamic measurements with the ultrasound cardiac output monitor (USCOM). Fluid resuscitation is guided by USCOM measurements. Receives: Other: USCOM-guided fluid administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time on vasopressors, measured during the 48 hours after study enrollment
Measured: 48 hours after study enrollment
Secondary outcomes (8)
ICU length of stay
Measured: At one month (average)
Hospital length of stay
Measured: At one month (average)
Duration of mechanical ventilation
Measured: At one month (average)
Development of acute renal failure
Measured: At one month (average)
Invasive procedures performed after study enrollment
Measured: At one month (average)
Intravenous fluids infused in first 2 hours after enrollment
Measured: First 2 hours after study enrollment
Intravenous fluids infused in first 48 hours after enrollment
Measured: First 48 hours after study enrollment
Need for hemodialysis
Measured: At one month (average)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Mar 2011 (estimated)
- Study startJan 2010
- Primary completionDec 2010
- Study completionDec 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypotensionStudies of the same condition, open and under way.
- More trials run by Washington University School of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 92 participants (actual)
Sponsor and investigators
- Lead sponsor
- Washington University School of Medicine
- Sponsor type
- University, hospital or other
- Investigators
- Lee M Demertzis, MD, Principal investigator, Barnes-Jewish HospitalMarin H Kollef, MD, Study director, Washington University School of MedicineWarren Isakow, MD, Study director, Washington University School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01309724
- Sponsor's protocol ID
- 09-1074
- Status last verified
- Mar 2011
- First submitted
- 2 Mar 2011
- Last updated
- 7 Mar 2011
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Mar 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- HEMODYNAMIC OPTIMIZATION BY NON-INVASIVE DETERMINATION OF CARDIAC OUTPUT IN CRITICALLY ILL PATIENTS: A RANDOMIZED, CONTROLLED TRIAL
- ClinicalTrials.gov ID
- NCT01309724
- Acronym / sponsor ID
- 09-1074
- Conditions
- Hypotension
- Keywords
- Hypotension, Fluid
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 92 participants (actual)
- Lead sponsor
- Washington University School of MedicineUniversity, hospital or other
- Study start
- Jan 2010
- Primary completion
- Dec 2010 (actual)
- Study completion
- Dec 2010 (actual)
- First posted
- 7 Mar 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Inadequate identification of and subsequent delayed therapy for patients with hypoperfusion (including hypovolemia, congestive heart failure and sepsis) is a common problem faced by physicians and intensivists caring for critically ill patients. Bedside clinical assessment is notoriously inaccurate in diagnosing complex etiologies of hemodynamic disturbances and in deciding on the appropriate therapy. Invasive techniques which are often required to guide diagnosis and therapy have significant risks associated with them, are costly, and are time consuming. New technology has been developed that allows for instantaneous, noninvasive monitoring of key hemodynamic parameters, like stroke volume, peak velocity and cardiac output. This new technology has the potential to improve recognition of the etiology of hemodynamic disturbances and assist the clinician in optimizing therapy based on changes in hemodynamic parameters. There is significant potential for this to be translated into improved outcomes in critically ill patients, but this has never been studied.
Detailed description
Patients with life-threatening hypotension are commonly cared for in intensive care units (ICUs). Pathophysiologic perturbations due to disease states such as sepsis, hypovolemia, and congestive heart failure may lead to tissue hypoxia, a critical development which precedes multi-organ failure and death. Not only is it difficult to rapidly identify patients heading down this path, but the execution of effective hemodynamic resuscitation to slow or reverse this process is challenging.
A cornerstone of hemodynamic resuscitation is volume administration. The goal of volume administration is to maximize cardiac output, and thereby systemic oxygen delivery, by optimizing cardiac preload. Bedside clinical assessment is inadequate for judging whether or not this goal has been achieved. Invasive techniques, such as central venous pressure (CVP) monitoring and pulmonary artery catheterization, carry risks, are costly and time-consuming, and may yield misleading data. Doppler ultrasound-based technology has been developed that allows for instantaneous, non-invasive monitoring of key hemodynamic parameters, such as cardiac output. This technology may facilitate determining the etiology of hemodynamic disturbances and assist the clinician in optimizing therapy based on changes in hemodynamic parameters. This randomized, controlled trial was designed to determine the impact of a volume resuscitation protocol, guided by non-invasive Doppler ultrasound technology, on outcomes in medical ICU patients with vasopressor-dependent hypotension.
Materials and methods:
Patient Population:
Study participants were recruited between January 19, 2010 and December 26, 2010 from two medical ICUs at Barnes-Jewish Hospital, a 1252-bed urban teaching hospital. The Washington University School of Medicine Human Research Protection Office approved the study, and informed consent was obtained from participants or their authorized representatives. Inclusion criteria were age ≥18 years; administration of vasopressors, defined as a continuous infusion of norepinephrine at a dose >5 mcg/min, dopamine ≥5 mcg/kg/min or any dose of another vasopressor; and passage of <18 hours since initiation of vasopressors at doses specified above. Exclusion criteria were hemorrhagic shock, need for immediate surgery, imminent risk of death in the next 48 hours (as judged by the attending ICU physician), level of care decision that precluded implementation of the study protocol, enrollment in any other clinical study, and pregnancy.
Study Protocol:
Subjects were assigned to treatment groups using blocked randomization to receive either volume resuscitation guided by the ultrasound cardiac output monitor (USCOM; USCOM Ltd., Sydney, Australia) or observation. The USCOM is a non-invasive device that uses continuous-wave Doppler ultrasound measurements of blood flow in the ascending aorta or pulmonary artery to estimate stroke volume (SV). Prior to the beginning of the study, one of the study investigators (LMD) underwent a supervised training period with the USCOM in 50 patients to insure reproducibility of the obtained measurements. Subjects randomized to the intervention group underwent a baseline USCOM measurement of SV by a single operator (LMD), followed by a pressurized infusion of 1 L of normal saline (NS) over approximately 15 minutes, after which the SV measurement was repeated. If the SV increased by ≥15%, the patient was deemed volume-responsive, and another 1 L NS bolus was administered. This process was repeated until the SV did not increase by ≥15%, two hours had elapsed since study enrollment, or 4 L of NS had been infused, whichever occurred first. With the exception of initial fluid management in the intervention group, as described above, use of all diagnostic and treatment modalities were at the discretion of the ICU physicians. Subjects in the control group underwent no intervention; ongoing care was carried out at the discretion of the ICU physicians. ICU physicians were unaware of subjects' group assignments and the USCOM data acquired in the intervention group.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control | No intervention | –No measurements are made on the control group. |
| USCOM | Experimental | Other: USCOM-guided fluid administrationPatients undergo hemodynamic measurements with the ultrasound cardiac output monitor (USCOM). Fluid resuscitation is guided by USCOM measurements. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age 18 yrs or greater
- Administration of vasopressors, defined as a continuous infusion of norepinephrine at a dose >5 mcg/min, dopamine ≥5 mcg/kg/min or any dose of another vasopressor
- Passage of <18 hours since initiation of vasopressors at doses specified above
Key exclusion criteria (6 listed)
- Hemorrhagic shock
- Need for immediate surgery
- Imminent risk of death in the next 48 hours (as judged by the attending ICU physician)
- Level of care decision that precluded implementation of the study protocol
- Enrollment in any other clinical study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| USCOM-guided fluid administrationAlso: Ultrasound cardiac output monitorPatients in the intervention group underwent hemodynamic measurements with the ultrasound cardiac output monitor. Based on these measurements, patients were guided through a fluid resuscitation protocol. | Other | USCOM |
Primary outcome
Time on vasopressors, measured during the 48 hours after study enrollment
Time frame: 48 hours after study enrollment
8 secondary outcomes
ICU length of stay
Time frame: At one month (average)
Hospital length of stay
Time frame: At one month (average)
Duration of mechanical ventilation
Time frame: At one month (average)
Development of acute renal failure
Time frame: At one month (average)
Invasive procedures performed after study enrollment
Time frame: At one month (average)
Intravenous fluids infused in first 2 hours after enrollment
Time frame: First 2 hours after study enrollment
Intravenous fluids infused in first 48 hours after enrollment
Time frame: First 48 hours after study enrollment
Need for hemodialysis
Time frame: At one month (average)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Mar 2011.
Related trials for Hypotension
Not yet recruitingObservational study
Diastolic Shock Index for Predicting Hemodynamic Instability During Continuous Renal Replacement Therapy
Acute Kidney Injury, Hypotension (MeSH: D007022)
RecruitingObservational study
Norepinephrine in the Management of General Anesthesia-Induced Arterial Hypotension in Chronic Heart Failure Patients
Hypotension
RecruitingPhase 4
Remimazolam Versus Propofol for Maintenance of Anaesthesia During Major Hepatectomy Under Low Central Venous Pressure
Intraoperative Hypotension, Hepatectomy
Not yet recruitingPhase 4
Effect of Ondansetron on the Incidence of Spinal Anaesthesia-Induced Hypotension in Elderly Patients Undergoing Fracture Hip Surgery
Spinal Anaesthesia Induced Hypotension
Not yet recruitingObservational study
Postprandial Hypotension, Frailty and Post-Induction Hypotension in Older Patients Undergoing Noncardiac Surgery
Post-induction Hypotension (PIH), Postprandial Hypotension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lee M Demertzis, MD principal investigator
Barnes-Jewish Hospital
Marin H Kollef, MD study director
Washington University School of Medicine
Warren Isakow, MD study director
Washington University School of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing USCOM-guided fluid administration in people with Hypotension, run by Washington University School of Medicine at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Mar 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time on vasopressors, measured during the 48 hours after study enrollment (time frame: 48 hours after study enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2011.